Publicaciones (71) Publicaciones en las que ha participado algún/a investigador/a

2017

  1. 18F-fluoromisonidazole PET and activity of neoadjuvant nintedanib in early HER2-negative breast cancer: A window-of-opportunity randomized trial

    Clinical Cancer Research, Vol. 23, Núm. 6, pp. 1432-1441

  2. A definition for aggressive disease in patients with HER-2 negative metastatic breast cancer: an expert consensus of the Spanish Society of Medical Oncology (SEOM)

    Clinical and Translational Oncology, Vol. 19, Núm. 5, pp. 616-624

  3. A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients

    Journal of Translational Medicine, Vol. 15, Núm. 1

  4. A randomized phase II/III study of cabazitaxel versus vinflunine in metastatic or locally advanced transitional cell carcinoma of the urothelium (SECAVIN)

    Annals of oncology : official journal of the European Society for Medical Oncology, Vol. 28, Núm. 7, pp. 1517-1522

  5. Advanced stage yolk sac ovarian tumour: Clinical approach with cytoreductive surgery upfront

    European Journal of Gynaecological Oncology, Vol. 38, Núm. 2, pp. 311-313

  6. An integrative approach unveils FOSL1 as an oncogene vulnerability in KRAS-driven lung and pancreatic cancer

    Nature Communications, Vol. 8

  7. Analysis of mutant allele fractions in driver genes in colorectal cancer – biological and clinical insights

    Molecular Oncology, Vol. 11, Núm. 9, pp. 1263-1272

  8. Anti-CD137 and PD-1/PD-L1 antibodies en route toward clinical synergy

    Clinical Cancer Research, Vol. 23, Núm. 18, pp. 5326-5328

  9. Antigen cross-presentation and T-cell cross-priming in cancer immunology and immunotherapy

    Annals of Oncology, Vol. 28, pp. xii44-xii55

  10. Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial

    The Lancet, Vol. 389, Núm. 10064, pp. 67-76

  11. Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: Post-progression outcomes from the phase II IMvigor210 study

    Annals of Oncology, Vol. 28, Núm. 12, pp. 3044-3050

  12. Axitinib treatment in advanced RAI-resistant differentiated thyroid cancer (DTC) and refractory medullary thyroid cancer (MTC)

    European Journal of Endocrinology, Vol. 177, Núm. 4, pp. 309-317

  13. Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors)

    European Journal of Cancer, Vol. 84, pp. 202-211

  14. Beurteilung der intraoperativen 3D-Bildgebungsalternativen für IOERT-Dosisabschätzung

    Zeitschrift fur Medizinische Physik, Vol. 27, Núm. 3, pp. 218-231

  15. Brachytherapy attains abscopal effects when combined with immunostimulatory monoclonal antibodies

    Brachytherapy, Vol. 16, Núm. 6, pp. 1246-1251

  16. Capecitabine and temozolomide in grade 1/2 neuroendocrine tumors: A Spanish multicenter experience

    Future Oncology, Vol. 13, Núm. 7, pp. 615-624

  17. Cervical cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Annals of Oncology, Vol. 28, pp. iv72-iv83

  18. Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in melanoma and non-small-cell lung cancer patients

    Annals of Oncology, Vol. 28, Núm. 8, pp. 1988-1995

  19. Chronic opioid therapy in long-term cancer survivors

    Clinical and Translational Oncology, Vol. 19, Núm. 2, pp. 236-250

  20. Clinical features and short-term outcomes of cancer patients with suspected and unsuspected pulmonary embolism: The EPIPHANY study

    European Respiratory Journal, Vol. 49, Núm. 1